CLINICAL REPORT. Outcomes associated with transdermal nicotine replacement therapy in a neurosurgery intensive care unit

Panos, Nicholas G.; Tesoro, Eljim P.; Kim, Keri S.; Mucksavage, Jeffrey J.
August 2010
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1357
Academic Journal
Purpose. The outcomes associated with transdermal nicotine replacement therapy NRT) in a neurosurgery intensive care unit ICU) were studied. Methods. Data from pharmacy records, neurosurgery ICU admission logs, and computerized patient charts at the University of Illinois Medical Center at Chicago from January 2001 through August 2008 were reviewed for patients older than 18 years who were admitted to the neurosurgery ICU for neurologic insults. Patients were categorized into three groups: smokers who received transdermal NRT (n = 114), smokers who did not receive transdermal NRT (n = 113), and nonsmokers (n = 113). The primary outcome of this study was unfavorable disposition at discharge from the hospital. Secondary outcomes measured included overall mortality; lengths of hospital and neurosurgery ICU stays; and rates of subarachnoid hemorrhage (SAH) rebleeding, angiographic vasospasm, intracerebral hemorrhage rebleeding, and ischemic stroke. Results. Overall, there was no difference in unfavorable discharge disposition among the three groups (p = 0.17). However, the group who received NRT had higher admission rates of SAH, smoked more cigarettes for a longer period of time, and had longer stays in the neurosurgery ICU and hospital compared with the other groups. All patients who received NRT had prolonged hospital (p = 0.014) and neurosurgery ICU (p = 0.006) stays compared with those who did not receive NRT. There were no differences in other secondary outcomes among the groups. Conclusion. There was no significant difference in unfavorable discharge disposition among neurosurgery ICU patients who were smokers treated with NRT, smokers not treated with NRT, and nonsmokers not treated with NRT.


Related Articles

  • Effectiveness of nicotine gum in smoking cessation.  // American Family Physician;1/1/1996, Vol. 53 Issue 1, p329 

    Discusses the article `Nicotine gum, 2 and 4 mg, for nicotine dependence,' by N. Herreraet al, published in `Chest.' Quitting chance of low-dependent smokers given two-mg nicotine gum; Quitting chance of high-dependent smokers given two-mg nicotine gum.

  • There are always handcuffs.  // U.S. News & World Report;6/14/93, Vol. 114 Issue 23, p33 

    Reports that Food and Drug Administration (FDA) Commissioner David Kessler has banned all nonprescription pills, lozenges and gum marketed as stop-smoking aids, none of which, so far, have proved to be effective. Support of the ban by various organizations.

  • The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Schneider, N.G.; Olmstead, R.E.; Franzon, M.A.; Lunell, E. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 9, p661 

    Nicotine inhaled in smoke is the most rapid form of delivery of the drug. With smoking, arterial boli and high venous blood nicotine concentrations are produced within seconds and minutes, respectively. The potency of nicotine as the primary reinforcement in tobacco addiction is attributed to...

  • Patch not a problem for cardiac patients. Mark, Anita M. // Journal of the American Dental Association (JADA);Feb97, Vol. 128 Issue 2, p164 

    Reports on the safety of using nicotine patch on patients with history of heart problems. Use of the nicotine patch in smoking cessation; Effectiveness of the patch.

  • European parliament refuses to classify e-cigarettes as a drug. Watson, Rory // BMJ: British Medical Journal;10/12/2013, Vol. 347 Issue 7928, p1 

    The article reports on the objection by the European parliament to the call for classifying electronic cigarettes as medicines in 2013.

  • Chancing your arm on nicotine patches. Saul, Helen // New Scientist;2/13/93, Vol. 137 Issue 1860, p12 

    Reports on the lack of evidence to show that nicotine patches on their own will help people to stop smoking. Three brands of patches licensed in Britain; Problems with the patch; What wearers' success largely depends on.

  • Should you try a nicotine patch or gum to quit smoking? E.G.; Young, Stephanie // Glamour;Sep96, Vol. 94 Issue 9, p82 

    Reports that a study shows that nicotine patch helps smokers quit sooner, for a longer period of time and with fewer side effects that nicotine gum.

  • High-dose nicotine: The 44-mg patch is strong, but for...  // Modern Medicine;Dec95, Vol. 63 Issue 12, p21 

    Reports on two studies on the use of nicotine patches to help people quit smoking. Comments by Michael C. Fiore, MD, MPH (Masters of Public Health) and Lowell C. Dale, MD; Study methods.

  • Nicotine trade off?  // Total Health;Dec94, Vol. 16 Issue 6, p11 

    Reports on the possible merits of nicotine nasal spray as an aid in smoking cessation. Review by the Food and Drug Administration's (FDA) advisory board; Comparison with the effectiveness of nicotine patches or gum.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics